Disease · MONDO_0009891

acquired polycythemia vera

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acquired polycythemia vera. Diseases, record MONDO_0009891. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0009891

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acquired polycythemia vera; Open Targets
Open Targets ID: MONDO_0009891; Open Targets
Other names: Osler-Vaquez disease, Osler-Vaquez syndrome, PV, Vaquez disease, acquired primary erythrocytosis, polycythaemia rubra vera, polycythemia rubra vera, polycythemia vera, polycythemia vera, somatic, proliferative polycythaemia; Open Targets
Disease Ontology: DOID:8997; Disease Ontology
MeSH: D011087; MeSH
NCI Thesaurus: C3336; NCI Thesaurus
Orphanet: ORPHA:729; Orphanet
Highest stage of its drugs: Approval, for 7 of its 52 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs52

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RUXOLITINIB	CHEMBL1789941	Small molecule	Approval	EMA Human Drugs	15	14	14	Drugs and targets
ROPEGINTERFERON ALFA-2B	CHEMBL4297819	Protein	Approval	EMA Human Drugs, FDA and TTD	17	13	8	Drugs and targets
PEGINTERFERON ALFA-2A	CHEMBL1201560	Protein	Approval	EMA Human Drugs	3	2	0	Drugs and targets
FEDRATINIB	CHEMBL1287853	Small molecule	Approval	TTD	2	1	1	Drugs and targets
MOMELOTINIB DIHYDROCHLORIDE	CHEMBL2219411	Small molecule	Approval	FDA	1	0	0	Drugs and targets
PACRITINIB CITRATE	CHEMBL5095049	Small molecule	Approval	FDA	1	0	0	Drugs and targets
RUXOLITINIB PHOSPHATE	CHEMBL1795071	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
HYDROXYUREA	CHEMBL467	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Phase 3	ClinicalTrials.gov	7	7	2	Drugs and targets
GIVINOSTAT	CHEMBL1213492	Small molecule	Phase 3	ClinicalTrials.gov	7	5	5	Drugs and targets

1 to 10 of 52

See all 52 drugs

Targets83

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK2	Tyrosine-protein kinase JAK2	8	Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
ABL1	Bcr/Abl fusion protein	5	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3455	Drugs and targets
BCR	Bcr/Abl fusion protein	4	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	3	Tyrosine-protein kinase receptor FLT3 inhibitor	Approval	https://conductscience.org/library/genes/2322	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	3	Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	3	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	3	Platelet-derived growth factor receptor beta inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
ACVR1	Activin receptor type-1	2	Activin receptor type-1 inhibitor	Approval	https://conductscience.org/library/genes/90	Drugs and targets

1 to 10 of 83

See all 83 targets

Trials66

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01243944	Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)	Phase 3	222	2015-03-06	Polycythemia Vera	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT01259856	Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)	Phase 3	168	2018-07-24	High Risk Polycythemia Vera, High Risk Essential Thrombocythemia	HYDROXYUREA, INTERFERON ALFA-2A	Its record names the disease	ClinicalTrials.gov
NCT02292446	Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.	Phase 3	161	2019-04-02	Polycythemia Vera	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT02038036	Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.	Phase 3	149	2021-07-20	Polycythemia Vera	ANAGRELIDE, HYDROXYUREA, PIPOBROMAN, RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT00038675	Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate	Not applicable	125	2022-01-04	Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome, Mastocytosis	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT01632904	Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study	Phase 3	110	2015-04-07	Polycythemia Vera	HYDROXYUREA, RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT02124746	Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia	Phase 2	87	2021-02-05	Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia	MOMELOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00669578	CC-4047 in Treating Patients With Myelofibrosis	Phase 1/2	77	2014-05-09	Chronic Myeloproliferative Disorders, Secondary Myelofibrosis	POMALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00726232	Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia	Phase 2	73	2012-02-24	Myeloproliferative Neoplasm (MPN)	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT00255346	Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)	Phase 2	68	2019-05-06	Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic	DASATINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 66

See all 66 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
PEGASYS vs Hydroxyurea: Number of Participants With Major Cardiovascular Events After Therapy	1 of 82	1 of 86	168	NCT01259856	Trial comparisons
PEGASYS vs Hydroxyurea: deaths from any cause	0 of 82	1 of 86	168	NCT01259856	Trial comparisons
PEGASYS vs Hydroxyurea: serious adverse events	14 of 82	4 of 86	168	NCT01259856	Trial comparisons
Ruxolitinib vs Best Available Therapy (BAT): Number of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 28	7 of 74	0 of 75	149	NCT02038036	Trial comparisons
Ruxolitinib vs Best Available Therapy (BAT): Number of Participants Achieving a Complete Hematological Remission at Week 28	17 of 74	4 of 75	149	NCT02038036	Trial comparisons
Ruxolitinib vs Best Available Therapy (BAT): Number of Participants With Transformation Free Survival Events	4 of 74	3 of 75	149	NCT02038036	Trial comparisons
Ruxolitinib vs Best Available Therapy (BAT): Number of Participants Developing Thrombosis	0 of 74	0 of 75	149	NCT02038036	Trial comparisons
Ruxolitinib vs Best Available Therapy (BAT): Number of Participants Achieving Hematocrit (Hct) Control at Week 28	46 of 74	14 of 75	149	NCT02038036	Trial comparisons
Ruxolitinib vs Best Available Therapy (BAT): Number of Participants With Overall Survival (OS) Events	3 of 74	6 of 75	149	NCT02038036	Trial comparisons
Ruxolitinib vs Hydroxyurea: serious adverse events	5 of 54	4 of 56	110	NCT01632904	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials38

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30409796	RESULT	1	PubMed
42751490	DERIVED	1	PubMed
42611791	DERIVED	1	PubMed
42588744	DERIVED	1	PubMed
41890273	DERIVED	2	PubMed
40775758	DERIVED	2	PubMed
40313042	DERIVED	2	PubMed
38381675	DERIVED	1	PubMed
38320126	DERIVED	1	PubMed
37592092	DERIVED	1	PubMed

1 to 10 of 38

See all 38 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0009891

GET https://conductscience.org/api/diseases/v1/MONDO_0009891/drugs?page=2

API reference For AI assistants